PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Resolution of Sickle Cell Leg Ulcers With Voxelotor
- Conditions
- Sickle Cell DiseaseLeg Ulcers
- Interventions
- Other: Placebo
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 88
- Registration Number
- NCT05561140
- Locations
- 🇰🇪
KEMRI-Centre for Respiratory Diseases Research-Nairobi, Nairobi, Kenya
🇰🇪Strathmore University Medical Centre, Nairobi, Kenya
🇰🇪KEMRI-CRDR, KEMRI Clinical Research Annex, Siaya, Kenya
Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.
- Conditions
- Hereditary Transthyretin Amyloidosis (ATTRv)Polyneuropathy
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT05560555
- Locations
- 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇪🇸Hospital Universitari de Bellvitge, Barcelona, Spain
🇪🇸Hospital Son Llatzer, Palma de Mallorca, Spain
A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT05554237
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT05549323
- Locations
- 🇺🇸
IHS Health Research, Kissimmee, Florida, United States
🇺🇸Kissimmee Endosocpy Center ( Endoscopy Only ), Kissimmee, Florida, United States
🇺🇸Orlando Diagnostic Center ( CXR Only ), Kissimmee, Florida, United States
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT05548127
- Locations
- 🇺🇸
Stanford Women's Cancer Center, Palo Alto, California, United States
🇺🇸UCSF Medical Center at Mission Bay, San Francisco, California, United States
🇺🇸Moffitt Cancer Center - International Plaza, Tampa, Florida, United States
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
- Conditions
- Coronavirus Disease 2019 (COVID-19)HospitalizationChild, HospitalizedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Immunocompromised
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05545319
- Locations
- 🇧🇬
Multiprofile Hospital for Active Treatment - Sveti Nikolay Chudotvoretz, Lom, Montana, Bulgaria
🇧🇬Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases - Haskovo EOOD, Haskovo, Bulgaria
🇧🇬"University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski" EAD, Pleven, Bulgaria
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
- Conditions
- Non-small Cell Lung CancerLoss of AppetiteColorectal CancerCachexiaPancreatic CancerFatigue
- Interventions
- Drug: Placebo for ponsegromab
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 187
- Registration Number
- NCT05546476
- Locations
- 🇪🇸
Hospital Universitario HM Sanchinarro, Madrid, Spain
🇪🇸Hospital Universitari i Politecnic La Fe, València, Spain
🇨🇳Chi Mei Hospital - Liouying Branch, Tainan City, Tainan, Taiwan
Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
- Conditions
- Biological Availability
- Interventions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05544786
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
- Conditions
- Influenza, Human
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45789
- Registration Number
- NCT05540522
- Locations
- 🇳🇿
P3 Research - Wellington, Wellington, New Zealand
🇵🇭De La Salle Health Sciences Institute, Dasmarinas City, Philippines
🇵🇭De La Salle Medical and Health Sciences Institute, Dasmarinas, Philippines
A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05538312
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium